Thousands of small investors expressed their disappointment at the meagre profits they made when shares of CK Life Sciences International (Holdings) debuted on the Growth Enterprise Market yesterday. Some bullish investors expected shares of the Li Ka-shing-controlled biotechnology venture to trade up to HK$2.50 from the issue price of HK$2. Instead, they peaked at only HK$2.27 before closing at HK$2.15 - up 7.5 per cent from the issue price. Retail investors who sold their individual allocations of 2,000 shares at the peak made a profit of only HK$350 after deducting broker's fees. Those who unloaded their shares at the HK$2.15 closing price made a net profit of just HK$100 from their 2,000 shares, which had cost them HK$4,100 - including broker's fees. Punters in Mr Li's Internet company, Tom.com, gained as much as HK$16,000 from their 2,000-share allocation from the Tom.com debut two years ago. From the issue price of HK$1.78, the share price rocketed to HK$8. A retail investor, Wong Yuk-mui, 70, said: 'My friends and I are very disappointed because the profit that we made is barely enough to buy us dinner. We bet our money on Li Ka-shing's fame and we expected CK Life's shares to move up about 50 per cent on the first day.' She made a profit of just HK$150 when she sold 2,000 shares at HK$2.17. The retail portion of CK Life's shares was 120 times oversubscribed, setting the stage for punters' high expectations yesterday. Tung Tai Securities associate director Kenny Tang Sing-hing, who expected the share to reach HK$2.50, blamed the poorer showing on the bearish sentiment in the United States equities market and heavy selling pressures from retail investors. CK Life Sciences chairman Victor Li Tzar-kuoi was happy with the pricing and turnover of HK$1.45 billion during the debut, which saw the firm become the GEM's biggest listing, with a market capitalisation of HK$13.77 billion, followed by sister company Tom.com with HK$10.89 billion.